The Efficiency of UPAC Deep Freezer in the Production of Cryoprecipitate from Regional Blood Centre 9th Phitsanulok, Thai Red Cross Society
Keywords:Cryoprecipitate,, UPAC deep freezer,, Factor VIII,, Fibrinogen
Objective: To study the efficiency of Deep freezer eutectic plate brand The Cool model DF 160 (UPAC
deep freezer) in the production of Cryoprecipitate (CRYO) from CRYO quality test results analysis
prepared by the Regional Blood Centre 9th Phitsanulok, Thai Red Cross Society compared to the standards
of the American Association of Blood Banks (AABB).
Methods: This is a retrospective, descriptive study on the results of FVIII and fibrinogen
content in 120 units of CRYO prepared by UPAC deep freezer from the Regional Blood Centre 9th Phitsanulok
between April 2015 and March 2019, during a four-years period. Sampling the CRYO produced in 6
units/3 months and studies of FVIII and fibrinogen content compared to AABB standards were performed
by the National Blood Centre, Thai Red Cross Society. Documented data was evaluated using
descriptive statistics and statistical analysis was performed by one sample T-test, independent T-test,
ANOVA and Scheffe’s method with significant at 0.05.
Results: CRYO 96 units of first month test found that average FVIII and fibrinogen content in CRYO
produced passed through standard criteria of AABB equal to 100 and 100 percent, with an average and
standard deviation (range) equal to 132.63±20.96 (89.39-204.29) IU/units and 558.59±179.99 (223.86-
958.95) mg/units, respectively. According to the grouping among the samples, the average FVIII content
in CRYO such as CRYO volume (p < 0.001) and donors ABO blood group (p = 0.013) were differences
statistically significant. The average fibrinogen content in CRYO such as CRYO volume (p < 0.001) and
donor gender (p = 0.001) were differences statistically significant. CRYO 24 units of last month test
found that the average FVIII content in CRYO produced passed through standard criteria of AABB equal
to 100 percent, with an average and standard deviation (range) equal to 110.88±17.64 (82.06-154.44)
IU/units, found that the average FVIII content in last month test CRYO was lower than the first month
test CRYO. They were statistically significant (p = 0.001), but all passed the standard.
Conclusion: The efficient UPAC deep freezer can be used to produce CRYO quality that is not inferior
to the international standard of FVIII and fibrinogen content. However, that quantity may vary.
Considering factors such as CRYO volume, ABO blood group, and donor gender, that may affect CRYO
quality. Such data may be used as a guideline for the development of production in order to obtain the
high quality standard CRYO for further use. The UPAC deep freezer will reduce produce CRYO costs of
expensive equipment and less place, appropriate for an organization with limited area.
Keywords: Cryoprecipitate, UPAC deep freezer, Factor VIII, Fibrinogen
2. Kasper CK. Judith graham pool and the discovery of cryoprecipitate. Hemophilia. 2012;18:833–5.
3. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 14thed.
Strasbourg Cedex: Council of Europe; 2008.
4. Nascimento B, Goodnough LT and Lev JH. Cryoprecipitate therapy. Br J Anaesthesia. 2014;113(6):922–34
5. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the
use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28.
6. National Blood Centre, Thai Red Cross Society. Standards for blood banks and transfusion services. 4st ed.
Bangkok: Udom suksa; 2015.
7. Dhingra N. Screening donated blood for transfusion transmissible infections. World Health Organization;
2010. p. 24-31.
8. Sparrow RL, Greening DW, Simpson RJ. A protocol for the preparation of cryoprecipitate and cryodepleted
plasma. Meth Mol Biol. 2011;728:259-65.
9. Bejrachandra S, O’Charoen R, Opartkiattikul N, Siriboonrit U, Kaewkamol K, Sombatnimitsakul S, et al. As
sessment of cryoprecipitate preparation by two freezing techiques: InstaCool freezer and freezer. Thai J
Hematol Transfus Med. 1992;2(3):303-11.
10. Kasper CK, Myhre BA, McDonald JD, Nakasako Y, Feinstein DI. Determinants of factor VIII recovery in cryo
precipitate. Transfu-sion. 1975;15:312-22.
11. Kang EP. An improved thaw-siphon method for the cryoprecipitate preparation. Vox Sang. 1980;38:172-7.
12. Caudill JS, Nichols WL, Plumhoff EA, Schulte SL, Winters JL, Gastineau DA, et al. Comparison of coagulation
factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion. 2009;49:765–70.
13. Bejrachandra S, Chandanayingyong D, Visudhiphan S, Tumliang S, Kaewkamol K, Siribunrit U. Factor VIII,
factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
Southeast Asian J Trop Med Public Health. 1993;24 (Suppl 1):162-4.
14. Cardigan R, Philpot K, Cookson P, Luddington R. Thrombin generation and clot formation in methylene
blue-treated plasma and cryoprecipitate. Transfusion. 2009;49:696–703.
15. Omidkhoda A, Tabatabaei MR, Atarodi K, Karimi K, Froushani AR, Pourfathollan AA. A comparative study
of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran.
Blood Transfus. 2011;9:394-9.
16. Hoffman M, Koepke JA, Widmann FK. Fibrinogen content of low-volume cryoprecipitate. Transfusion
17. Bettigole RE, Tourbaf K, Robson EB, Schultz M. The effect of cryoprecipitate volume on factor VIII content.
18. Philip J, Kumarage S, Chatterjee T, Kumar S, Mallhi R. The possible advantages of cryoprecipitate prepared
from fresh frozen plasma from blood stored for 24 hours. Lab Med Spring. 2014;45:111-5.
19. Weisert O, Jeremic M. Plasma fibrinogen levels in 1,016 regular blood donors. Vox Sang. 1974;27:176-85.25.
20. Tarallo P, Henny J, Gueguen R, Siest G. Reference limits of plasma fibrinogen. Clin Chem Clin Biochem.
How to Cite
Copyright (c) 2021 Health Science Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.